BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

ORIONPHARM

All Eps Dividend Board Agm Q1 Q2 Q3

ORIONPHARM 31-Oct-2017

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 07, 2017 at 5:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2017.

ORIONPHARM 25-May-2017

Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Entity rating (Surveillance) of the Company as "A1" along with a stable outlook based on un-audited financial statements as of December 31, 2016, audited financial statement of the Company up to June 30, 2016; bank liability position as of April 30, 2017 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

ORIONPHARM 02-May-2017

(Q3 Un-audited): Consolidated EPS was Tk. 0.56 for January-March 2017 as against Tk. 0.33 for January-March 2016; Consolidated EPS was Tk. 3.02 for July'16-March'17 as against Tk. 2.33 for July'15-March'16. Consolidated NOCFPS was Tk. 8.54 for July 2016-March 2017 as against Tk. 10.23 for July 2015-March 2016. Consolidated NAV per share (including and excluding Revaluation Surplus) was Tk. 71.14 and Tk. 62.63 respectively as on March 31, 2017 and Tk. 69.99 and Tk. 61.34 respectively as on June 30, 2016.

ORIONPHARM 24-Apr-2017

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2017 at 5:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2017.

ORIONPHARM 26-Feb-2017

(Continuation news of ORIONPHARM): 10 equal and consecutive semi-annual payments, the first of which will be due on the earlier of 6 months after the date of commissioning and/or December 15, 2018. The loan agreement, the terms and conditions of which were agreed by the Company and the Lender on December 07, 2016, was subject to formal approval by the Bangladesh Investment Development Authority (BIDA). BIDA has approved the agreement and has given the permission on February 22, 2017. (end)

ORIONPHARM 26-Feb-2017

(Continuation news of ORIONPHARM): will be drawn down in 2 tranches against pro rata deliveries made/services rendered in accordance with the relevant provisions under the export contract by M/s Ferrostaal Equipment Solutions, GmbH, Germany and HERMES for ECA premium. The loan will attract interest at the rate of 2.15% per annum above LIBOR in addition. The lender will receive management fees and commitment fees. Repayment will be made over 5 years excluding delivery and commissioning period in (cont. 2)

ORIONPHARM 26-Feb-2017

The Company has informed that the Company has entered into a new loan agreement with BHF-Bank Aktiengesellshaft, Frankfurt am Main, Federal Republic of Germany to borrow up to US$ 34.281 million to partially finance the purchase of new plant and machinery to expand its production facilities. It will be covered by Hermes (German Export Credit Agency Euler Hermes Aktiengesellshaft, Hamburg) guarantee. The Loan, which is secured on the plant and machinery being purchased, (cont. 1)

ORIONPHARM 01-Feb-2017

(Continuation news of ORIONPHARM): Consolidated NAV per share with revaluation surplus was Tk. 70.72 as of December 31, 2016 and Tk. 69.99 as of June 30, 2016. Consolidated NAV per share without revaluation surplus was Tk. 62.17 as of December 31, 2016 and Tk. 61.34 as of June 30, 2016. (end)

ORIONPHARM 01-Feb-2017

(Q2 Un-audited): Consolidated EPS was Tk. 1.29 for October-December, 2016 as against Tk. 1.27 for October-December, 2015; Consolidated EPS was Tk. 2.46 for July-December, 2016 as against Tk. 2.00 for July-December, 2015. Consolidated NOCFPS was Tk. 3.22 for July-December, 2016 as against Tk. 4.71 for July-December, 2015. (cont.)

ORIONPHARM 24-Jan-2017

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 31, 2017 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2016.

Previous Next page